Alpha-1 Antitrypsin Deficiency Clinical Trial
Official title:
A Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 1 Study to Determine the Safety, Tolerability, Pharmacokinetics and Effect of Circulating Alpha-1 Antitrypsin Levels of ARC-AAT in Healthy Volunteer Subjects and in Patients With Alpha-1 Antitrypsin Deficiency (AATD)
The purpose of the study is to determine the safety and tolerability of escalating doses of ARC-AAT and to evaluate the pharmacokinetics of ARC-AAT and the effect of ARC-AAT on circulating levels of alpha-1 antitrypsin (AAT). The study will consist of two parts, Part A (conducted in healthy volunteers) and Part B (conducted in AATD patients) at up to 9 escalating dose levels with 6 participants per dose level.
Healthy volunteers and AATD patients will be randomized to receive a single intravenous injection of either ARC-AAT or Placebo in double-blind fashion. Up to thirteen cohorts (6 participants per cohort) will be enrolled. Participants in all cohorts will be confined to the clinical facility beginning on Day -1 with discharge on Day 2. Escalation to the next dose level will proceed until a participant experiences a dose-limiting toxicity (DLT) or there is achievement of pre-determined threshold reductions in AAT levels. Dosing in participants with AATD will commence based on pre-determined threshold reductions in AAT levels for healthy volunteers. For each participant, the duration of the study clinic visits is up to 11 weeks, from Screening to the End-of-Study examination. However, including a Day 90 Follow-Up telephone call, the maximum study duration is approximately 20 weeks. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02547532 -
Microbioma in Sputa From COPD With Alpha-1 Antitrypsin Deficiency
|
||
| Completed |
NCT01615484 -
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
|
N/A | |
| Completed |
NCT00005292 -
Alpha1-antitrypsin Deficiency Registry
|
N/A | |
| Withdrawn |
NCT02900183 -
Safety, Tolerability and Effect of ARC-AAT Injection on Circulating and Intrahepatic Alpha-1 Antitrypsin Levels
|
Phase 2 | |
| Terminated |
NCT02502201 -
Environment Effect on Six-Minute Walk Test Performance
|
N/A | |
| Completed |
NCT01810458 -
Liver Fibrosis in Alpha-1 Antitrypsin Deficiency (Liver AATD)
|
||
| Active, not recruiting |
NCT04262284 -
Respreeza® Self-administration and Learning Program (AmAREtTI Study)
|
||
| Recruiting |
NCT06186492 -
A Phase 1 Research Study to Evaluate Safety, Tolerability, and Pharmacokinetics of WVE-006 in Healthy Participants With Wild-type AAT Expression (RestorAATion-1)
|
Phase 1 | |
| Recruiting |
NCT06405633 -
A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD
|
Phase 1/Phase 2 | |
| Completed |
NCT01054339 -
Safety & Efficacy Study of rAAV1-CB-hAAT for Alpha-1 Antitrypsin Deficiency
|
Phase 2 | |
| Completed |
NCT03815396 -
Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency
|
Phase 1 | |
| Completed |
NCT03008915 -
Targeting Pulmonary Perfusion in Alpha-1 Antitrypsin Deficiency
|
Phase 2 | |
| Completed |
NCT01419158 -
Prevalence of Alpha-1 Antitrypsin Deficiency in Chronic Obstructive Pulmonary Disease (COPD)
|
N/A | |
| Recruiting |
NCT00500123 -
The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study
|
||
| Completed |
NCT05727800 -
A Phase 1, First-in-human Study of VX-668
|
Phase 1 | |
| Active, not recruiting |
NCT05643495 -
A Study to Evaluate Efficacy and Safety of VX-864 in Participants With the PiZZ Genotype
|
Phase 2 | |
| Completed |
NCT02810327 -
Alpha-1 Carrier Genomics Study
|
||
| Completed |
NCT03804021 -
Long-Term Follow-up Study of ADVM-043
|
||
| Active, not recruiting |
NCT02014415 -
Alpha-1 Antitrypsin Deficiency Adult Liver Study
|
||
| Terminated |
NCT01241942 -
Phase 2 Study of Ex-vivo Perfusion and Ventilation of Lungs to Assess Transplant Suitability
|
N/A |